Naltrexone: a possible therapeutic alternative?

Authors

  • Paula Johana Barba Dermatology Service, General Acute Hospital Prof. Dr. Rodolfo Rossi, La Plata, Province of Buenos Aires, Argentina

DOI:

https://doi.org/10.47196/da.v26i1.2063

Keywords:

Naltrexone, Drug

Abstract

Naltrexone is a competitive antagonist drug of classical opioid receptors (µ, d and k), approved in 1984 by the FDA for the treatment of opioid addiction in doses of 50-100 mg. Later, it was also approved and used in the treatment of alcohol dependence.

Author Biography

Paula Johana Barba, Dermatology Service, General Acute Hospital Prof. Dr. Rodolfo Rossi, La Plata, Province of Buenos Aires, Argentina

Dermatologist

References

I. Toljan K, Vrooman B. Low-dose Naltrexone (LDN)-Review of therapeutic utilization. Med Sci (Basel)2018;6:84.

II. Lee B, Elston DM. The uses of naltrexone in dermatologic conditions. J Am Acad Dermatol2019;80:1746-1752.

III. Campbell V, McGrath C, Corry A. Low-dose naltrexone: a novel treatment for Hailey-Hailey disease. Br J Dermatol2018;178:1196-1198.

IV. Jfri A, Litvinov IV, Netchiporouk E. Naltrexone for the treatment of Darier and Hailey-Hailey diseases. J CutanMed Surg2019;23:453-454.

V. Strazzulla LC, Avila L, Lo Sicco K, Shapiro J. Novel treatment using low-dose Naltrexone for lichen planopilaris. J Drugs Dermatol2017;16:1140-1142.

VI. Frech T, Novak K, Revelo MP, Murtaugh M, et ál. Low-dose naltrexone for pruritus in systemic sclerosis. Int JRheumatol2011;2011:804296.

VII. Bridgman AC, Kirchhof MG. Treatment of psoriasis vulgaris using low-dose naltrexone. JAAD Case Rep 2018;4:827-829.

Revista Dermatología Argentina Nº 1 de 2020

Downloads

Published

2020-03-02

Issue

Vol. 26 No. 1 (2020): January-March 2020

Section

Young Dermatologists

License

El/los autor/es tranfieren todos los derechos de autor del manuscrito arriba mencionado a Dermatología Argentina en el caso de que el trabajo sea publicado. El/los autor/es declaran que el artículo es original, que no infringe ningún derecho de propiedad intelectual u otros derechos de terceros, que no se encuentra bajo consideración de otra revista y que no ha sido previamente publicado.

 

Le solicitamos haga click aquí para imprimir, firmar y enviar por correo postal la transferencia de los derechos de autor